Sinopharm Group just posted its Q3 2026 scorecard and the share price closed at HK$16.3, with the stock roughly flat over the past week and month. On the surface that muted move suggests calm. The numbers tell a different story.
Basic earnings per share for the quarter came in at 3.143671 CNY and net income excluding one off items reached CNY 1,909.844 million, while the trailing 12 month P/E sits near 6x against far higher sector and peer averages. The market is treating this as business as usual. The valuation gap indicates that sentiment and the profit picture may not yet be aligned.
Like the earnings power at Sinopharm Group but wary that a low P/E can sometimes flag hidden risks rather than a bargain? Compare this setup with our 195 high quality undervalued stocks to see how other companies pair strong fundamentals with discounted valuations.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): CNY 144,813.8m vs. CNY 145,435.7m (broadly stable year on year)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): CNY 1,909.8m vs. CNY 1,841.1m (modest increase in underlying profit)
- Basic EPS (Q3 2026 vs Q3 2025): CNY 3.1437 vs. CNY 3.2875 (slight dilution in earnings per share)
- Trailing 12 Month Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): CNY 7,162.0m vs. CNY 7,077.8m (small uplift in full year underlying earnings)
Sinopharm screens far cheaper than its Hong Kong healthcare peers. Ask Charlie what makes Sinopharm’s low P/E look cheap.
Sinopharm bullish thesis meets a fragile earnings base
The memo leans on Sinopharm using its scale and integration to keep the machine running steadily even as the industry settles after COVID.
"Vertical integration supports resilience"
Q3 results show pieces of that resilience but not a clean win. Revenue of CNY 144,813.8m is broadly in line with last year and trailing net income excluding extra items of CNY 7,162.0m is only slightly higher. Earnings per share dipped from CNY 3.2875 to CNY 3.1437. The group is holding ground rather than clearly turning scale and integration into a stronger profit engine.
Bear case on margins and cash strain still in play
Concerns focus on thin profitability and the risk that low prices and heavy working capital needs eat into Sinopharm’s flexibility.
"Working capital intensive distribution model"
Recent numbers do not contradict that worry. Revenue is broadly unchanged while underlying quarterly profit moved only modestly, which keeps net margin leverage limited. The memo highlights prior periods of negative operating cash flow. With earnings progress incremental and earnings per share slightly softer, the latest figures suggest the model remains sensitive to policy and pricing, with no clear sign yet that cash generation has structurally improved.
The price and this Narrative do not agree. → Uncover what this Narrative says Sinopharm Group is actually worth.
Hunt For Mispriced Earnings Power
Sinopharm Group just showed how a steady quarter can still leave questions about how the stock is priced. The real opportunity is finding stocks that could be undervalued before the market corrects them.
- Company 1 - 22% below our estimate - uses surgical robotics and higher acuity procedures to deepen penetration in joint replacement workflows.
- Company 2 - 32% below our estimate - scales a multi affiliate platform as new specialist managers plug into shared distribution and infrastructure.
- Company 3 - 34% below our estimate - grows a subscription based retail model while expanding recommerce and reverse logistics for traded in tech.
Three companies from the same screener. Open all 195 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com